News
J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...
Investor's Business Daily on MSN1d
AnaptysBio Earns RS Rating Upgrade
AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG ...
The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback